SRNE - Sorrento says fourth patient discharged following COVI-MSC treatment shares up 14%

Sorrento Therapeutics (SRNE) jumps 14% premarket following an update to the previous Phase 1b results of COVI-MSC study in COVID-19.On January 27, SRNE announced that the first three enrolled ICU COVID-19 patients were discharged from the hospital within a week of starting COVI-MSC infusions and a fourth patient just started the treatment.The fourth patient who had been in the hospital for more than 2 weeks and required intubation and mechanical ventilation was discharged the evening after his 3rd COVI-MSC infusion on January 29.No infusion related safety events were reported.SRNE surged ~31% over the past five days, following positive COVI-MSC study data.Also, amid ongoing retail-trading frenzy, Sorrento was added to Robinhood's list of 50 equities where buying shares and options contracts is limited.

For further details see:

Sorrento says fourth patient discharged following COVI-MSC treatment, shares up 14%